Health Trials

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

ConditionsColorectal CancerCRC (Colorectal Cancer)Cancer Cachexia
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNGM Biopharmaceuticals, Inc

About this trial

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Eligibility criteria

Qualifiers

Documented active diagnosis of colorectal cancer.

Cachexia defined by Fearon criteria of weight loss.

Signed informed consent.

Disqualifiers

Current active reversible causes of decreased food intake.

Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.

Have cachexia caused by other reasons.

Trial design

Treatments tested in this trial

  • NGM120 Q4W
  • NGM120 Q8W
  • Placebo given

Treatment groups

136 Participants
are divided into 5 treatment groups

Sponsors and collaborators

NGM Biopharmaceuticals, Inc

Lead sponsor

Source ClinicalTrials.gov